Erasca Announces FDA Clearance of UCLA Developed Drug

UCLA Researchers David Nathanson, Ph.D., Michael Jung, Ph.D., and Timothy Cloughesy, M.D. developed ERAS-801, an orally available small molecule epidermal growth factor receptor (EGFR) inhibitor specifically designed to have high central nervous system (CNS) penetration for the treatment of recurrent glioblastoma multiforme (rGBM). The company Erasca licensed ERAS-801 from Katmai Pharmaceuticals, Inc. and received FDA clearance.

UCLA and Amazon join forces to create Science Hub for Humanity and Artificial Intelligence


At a kickoff event on the anniversary of the birth of the internet, speakers included Pietro Perona and Prem Natarajan of Amazon, and Leonard Kleinrock, Jayathi Murthy, Andrea Ghez, Jens Palsberg and Stefano Soatto of UCLA.


Christine Wei-li Lee | October 29, 2021

Amazon and UCLA have collaborated to establish the Science Hub for Humanity and Artificial Intelligence, marking the technology company’s first such alliance with a public university.